PreveCeutical Medical Inc. (CNSX:PREV) Chairman and CEO Stephen Van Deventer joined Steve Darling from Proactive Investors to talk about the medical company that has recently filed two new patent applications for cyclic peptides and their use in pain management.
Van Deventer also talked about the company filing an application to a local hospital’s Human Ethics Committee to acquire human nasal mucosal tissue for the final phase of the cannabinoid-based, soluble gel.
Price: 0.03 CAD
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of PreveCeutical Medical Inc. named herein, including the promotion by the Company of PreveCeutical Medical Inc. in any Content on the Site, the...
FOR OUR FULL DISCLAIMER CLICK HERE
Preveceutical (CSE:PREV-OTCQB: PRVCF) President Mak Jawadeker joined Steve Darling from Proactive Vancouver on Skype to discuss the company successfully completing the design, synthesis and preliminary evaluation of key peptides from its scorpion venom-derived peptide research and development...
Retail & consumer
Industry & services
Prev article
